BioLamina

Steve Cronin

🇪🇸 Spain

8.8

Reviewed: July 5, 2023

• - Biostatistical Design
• - 4 weeks May - June 2023
• - Research Institution

The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.

Dr. Earnest Rogahn

🇪🇸 Spain

5.8

Reviewed: April 5, 2024

• - Biostatistical Design
• - 6 weeks February - March 2024
• - Research Institution

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.

Kurt Skiles

🇨🇭 Switzerland

6.3

Reviewed: November 7, 2024

• - Stability Studies
• - 16 months July 2023 - November 2024
• - Pharmaceutical Company

The stability studies conducted were lacking in detail, and we had to perform additional validation to ensure the results were reliable. This added extra time and cost to the project. The team was responsive to feedback, but the initial work was subpar.

Dr. Loretta Huel

🇮🇩 Indonesia

5.4

Reviewed: October 3, 2024

• - Process Development
• - 14 weeks June - September 2024
• - Biotech Company

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.

Pete Rodriguez I

🇩🇪 Germany

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.

Katie Mraz

🇳🇱 Netherlands

9.2

Reviewed: August 20, 2024

• - Regulatory Strategy Consulting
• - 4 weeks July - August 2024
• - Biotech Startup

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Pat Kirlin

🇯🇵 Japan

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Reginald Ullrich

🇮🇩 Indonesia

9

Reviewed: February 4, 2024

• - Biomarker Development
• - 12 weeks October 2023 - January 2024
• - Research Institution

The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.

Dr. Tommy Cremin I

🇲🇽 Mexico

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.